Skip to main content

Intended for Healthcare Professionals

Johnson and Johnson logo graphic link
/en-US
  • acclarent logo
  • biosense webster logo
  • cerenovus jjmdc logo
  • DePuy Synthes
  • Ethicon Logo
  • Mentor Logo

Intended for HCPs

Intended for Healthcare Professionals

Secondary nav block

ethicon
  • Home
  • Products
    • All Ethicon Products
    • Adjunctive Hemostats
    • Digital Solutions
    • Energy Sealing & Dissecting
    • LINX Reflux Management
    • MONARCH™ Platform
    • Neuwave Microwave Ablation
    • Surgical Stapling
    • Vascular Access & Infection Control
    • Wound Closure
    • Other Products
  • Order
  • Support
    • CA Compliance
    • Contributions and Donations
    • Clinical & Technical Support
    • Education Grants
    • Ethicon Product Center (Online Catalog)
    • Instructions for Use
    • Investigator-Initiated Studies
    • Johnson & Johnson Institute
    • Magnetic Resonance Imaging (MRI)
    • Medical Information Request (MIR)
    • Reimbursement
    • Supplemental Terms
  • About Us
    • Careers
    • News
    • Company
  1. Home
  2. Products
  3. LINX™ Reflux Management System

LINX™ Reflux Management System

LINX™ Reflux Management System

The LINX Reflux Management System is a laparoscopic, fundic-sparing anti-reflux procedure indicated for patients diagnosed with Gastroesophageal Reflux Disease (GERD). LINX™ is a flexible ring of small magnets placed around the lower esophageal sphincter (LES)—the strength of the magnets is precisely calibrated to help keep the weak LES closed to prevent reflux.

Contact a Representative
Instructions for Use
Find a LINX Surgeon
LINX™ Reflux Management System

IMAGES

LINX™ Reflux Management System
rgb(200,16,46)

An innovative surgical treatment for GERD clinically shown to produce consistent, lasting results.1-3*

99%

of patients reported no regurgitation 5 years after LINX™ treatment1†

88%

of patients reported no bothersome heartburn after 5 years.1‡

85%

of patients no longer needed PPIs after LINX™ treatment.1§

83%

A 50% or greater reduction in GERD-HRQL score was achieved in 83% of patients.1¶

Ethicon Logo

Features & Benefits

A revolutionary treatment for reflux disease

A revolutionary treatment for reflux disease

LINX™ augments the weak sphincter without compressing the esophagus. The dynamic opening and closing of the beads preserves physiological function, allowing patients to belch and vomit.3#

See how it works
Long-term efficacy

Long-term efficacy

In a long‐term follow‐up study, 89% of LINX patients at a median of 9 years post‐op met criteria for favorable long‐term outcomes4**

View study summary
Favorable safety profile

Favorable safety profile

With a low rate of device removals, rare occurrence of device erosions and no migrations seen in clinical trials, the clinical evidence supports LINX as an effective treatment for GERD with a favorable safety profile.1††

See the data
Supported by gastroenterological societies

Supported by gastroenterological societies

Recent guidelines/practice updates from the ACG and AGA include LINX™ as an effective surgical option for patients with evidence of GERD.5,6

Read ACG Guideline
rgb(9,31,44)

LINX™ is an effective option to treat GERD after Sleeve Gastrectomy

One-year results of a clinical trial of LINX™ in patients with persistent GERD following sleeve gastrectomy include:7

85%

were free from daily PPIs‡‡

81%

were free from moderate-to-severe heartburn8//

92%

were free from moderate-to-severe regurgitation§§

85%

were free from extra-esophageal symptoms¥

LINX™ Improved Quality of Life

LINX™ Improved Quality of Life

A one-year clinical trial evaluated the safety and efficacy of LINX™ in patients who have had prior a laparoscopic sleeve gastrectomy (LSG) procedure. 81% of LINX™ patients reported improved quality of life 12 months after treatment.7## Additionally, no device migrations or erosions were observed within 12 months of LINX™ treatment.7¥¥

Learn More About LINX™ After LSG
Video 1 of 3

Resources

How LINX Works
Now Playing

How LINX Works

01:17

Dr. John Lipham - Outcomes in Large Hiatal Hernia Patients
Now Playing

Dr. John Lipham - Outcomes in Large Hiatal Hernia Patients

02:37

Dr. John Pandolfino Discusses our Most Recent RCT
Now Playing

Dr. John Pandolfino Discusses our Most Recent RCT

02:39

Additional Resources

MR conditional

MR conditional

Patients with a LINX™ device can undergo a wide range of diagnostic imaging tests, including: X-Ray, ultrasound, PET scan, CT scan, and MRI under certain conditions.9

View MRI information
Updated sizing tool

Updated sizing tool

The LINX Reflux Management System Esophagus Sizing Tool is designed to enable one-handed use and sizing confidence.

See how it works

Supporting Documentation

Product Support
Product Support

Product Support

  • Post-Op Management Guide
    PDF Icon

    View PDF

  • LINX Patient Information Booklet US
    PDF Icon

    View PDF

  • FENIX Product Discontinuation Information
    PDF Icon

    View PDF

  • Select all documents (3)

References

* Individual results may vary

† Based on a 5 year prospective, multi-center, single-arm study observing 100 patients who were implanted with LINX, regurgitation was 57% at baseline and decreased to 1.2% at 5 years. (p<0.001)

‡ Based on a 100 patient, 5 year, prospective, multi‐center, single‐arm study of patients who were implanted with LINX, bothersome heartburn was 89% at baseline and decreased to 11.9% at 5 years. (p<0.001)

§ Based on a 5 year prospective, multi-center, single-arm study observing 100 patients who were implanted with LINX, daily use of PPIs was 100% at baseline and decreased to 15.3% at 5 years. (p<0.001)

¶ Based on a 5 year prospective, multi-center, single-arm study observing 100 patients who were implanted with LINX, the success criteria for quality of life (50% reduction in total GERD-HRQL score and 50% reduction in PPI use) were met.

# Based on a retrospective analysis of 1-year outcomes of patients undergoing MSA and LNF from June 2010 to June 2013. Matched-pair analysis of 100 patients. More LNF patients were unable to belch (8.5% of MSA and 25.5% of LNF; p= 0.028) or vomit (4.3% of MSA and 21.3% of LNF; p=0.004).

** Based upon a 6‐12 years follow up study of 124 patients. Favorable outcomes were defined as ≥ 50% improvement in GERD‐ HRQL total score and PPI discontinuation

†† Based on a prospective study of the safety and efficacy of magnetic devices in 100 adults. No device erosions, migrations, or malfunctions occurred in this study. Device removal occurred in 7 patients.

‡‡ 15.4% (4/26) of patients implanted with LINX, after laparoscopic sleeve gastrectomy, were on PPIs at 12 months vs. 100% at baseline. 

// Based on Foregut Symptom Questionnaire responses at 12 months (n=26) of patients implanted with LINX after laparoscopic sleeve gastrectomy.

§§ 7.7% (2/26) of patients implanted with LINX, after laparoscopic sleeve gastrectomy, had moderate-to-severe regurgitation at 1 year vs. 80% (24/30) at baseline.

¥ 15.4% (4/26) of patients implanted with LINX, after laparoscopic sleeve gastrectomy, experienced extra-esophageal symptoms at 1 year vs. 40% (12/30) at baseline

## 80.8% (21/26) of patients implanted with LINX, after laparoscopic sleeve gastrectomy, reported ≥50% reduction in GERD-HRQL from baseline to 12-month follow-up (p<0.001)

¥¥ Based on 12-month follow-up (n=26) of patients implanted with LINX after laparoscopic sleeve gastrectomy

1.    Ganz R. Edmundowicz S, Taiganides P, et al. Long‐term Outcomes of Patients Receiving a Magnetic Sphincter Augmentation Device for Gastroesophageal Reflux. Clin Gastroenterol Hepatol. 2016. 14(5):671‐7.

2.    Rona K, Reynolds J, Schwameis K, et al. Efficacy of magnetic sphincter augmentation in patients with large hiatal hernias. Surgical Endoscopy. 2017. 31(5):2096‐2102. 

3.    Reynolds J, Zehetner J, Wu P, et al. Laparoscopic Magnetic Sphincter Augmentation vs Laparoscopic Nissen Fundoplication: A Matched‐Pair Analysis of 100 Patients. J American College of Surgeons. 2015. 221(1):123‐128.

4.    Ferrari D, Asti E, Lazzari V, et al. Six to 12‐year outcomes of magnetic sphincter augmentation for gastroesophageal reflux disease. Sci Rep. 2020. 10(13753).

5.    Katz PO, Dunbar K, Schnoll-Sussman FH, Greer KB, Yadlapati R, Spechler SJ. ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease. Amer J Gastroenterol. 2022;117(1):27-56.

6.    Yadlapati R, Gyawali CP, Pandolfino JE. AGA Clinical Practice Update on the Personalized Approach to the Evaluation and Management of GERD: Expert Review. Clinical Gastroenterology and Hepatology. 2022;20(5):984-994.e1

7.    RELIEF Study: A Prospective, Multicenter Study of Refux Management with the LINX System for Gastroesophageal Refux Disease After Laparoscopic Sleeve Gastrectomy. Ethicon Inc., Internal Report. October 14, 2021.

8.    The LINX Refux Management System IDE Study Table 17b, Foregut Symptoms Questionnaire by Visit (Of PPI). Ethicon Inc., Internal Report. October 14, 2021.

9.    LINX Reflux Management System, Instructions for Use. Ethicon, Inc.

LINX™ Reflux Management System Important Safety Information

The LINX™ Reflux Management System is a laparoscopic, fundic-sparing anti-reflux procedure indicated for patients diagnosed with Gastroesophageal Reflux Disease (GERD) as defined by abnormal pH testing, and who are seeking an alternative to continuous acid suppression therapy (i.e. proton pump inhibitors or equivalent) in the management of their GERD.

Rx Only 

Contraindications: Do not implant the LINX Reflux Management System in patients with suspected or known allergies to titanium, stainless steel, nickel, or ferrous materials. 

Warnings: The LINX device is considered MR Conditional in a magnetic resonance imaging (MRI) system up to either 0.7 Tesla (0.7T) or 1.5 Tesla (1.5T), depending on the LINX model implanted. Scanning under different conditions may result in serious injury to you and/or interfere with the magnetic strength and the function of the device. In the event alternative diagnostic procedures cannot be used and MRI is required, the LINX device can be safely removed utilizing a laparoscopic technique that does not compromise the option for traditional anti-reflux procedures. It is recommended that patients receiving the LINX device register their implant with the MedicAlert Foundation (www.medicalert.org) or equivalent organization. 

Failure to secure the LINX device properly may result in its subsequent displacement and necessitate a second operation. 

General Precautions: The LINX device is a long-term implant. Explant (removal) and replacement surgery may be indicated at any time. Management of adverse reactions may include explantation and/or replacement.

The use of the LINX device in patients with a hiatal hernia larger than 3 cm should include hiatal hernia repair to reduce the hernia to less than 3 cm. The LINX device has not been evaluated in patients with an unrepaired hiatal hernia greater than 3 cm. 

The safety and effectiveness of the LINX device has not been evaluated in patients with Barrett's esophagus or Grade C or D (LA classification) esophagitis. 

The safety and effectiveness of the LINX device has not been evaluated in patients with electrical implants such as pacemakers and defibrillators, or other metallic, abdominal implants. 

The safety and effectiveness of the LINX Reflux Management System has not been established for the following conditions:

  • Scleroderma
  • Suspected or confirmed esophageal or gastric cancer
  • Prior esophageal or gastric surgery or endoscopic intervention with the exception of Laparoscopic Sleeve Gastrectomy (LSG) which has been evaluated for safety and efficacy.
  • Distal esophageal motility less than 35 mmHg peristaltic amplitude on wet swallows or <70% (propulsive) peristaltic sequences or High Resolution Manometry equivalent, and/or a known motility disorder such as Achalasia, Nutcracker Esophagus, and Diffuse Esophageal Spasm or Hypertensive LES
  • Symptoms of dysphagia more than once per week within the last 3 months
  • Esophageal stricture or gross esophageal anatomic abnormalities (Schatzki’s ring, obstructive lesions, etc.)
  • Esophageal or gastric varices
  • Lactating, pregnant or plan to become pregnant
  • Morbid obesity (BMI >35)
  • Age < 21

Potential Side Effects: Potential adverse events associated with laparoscopic surgery and anesthesia include adverse reaction to anesthesia (headache, muscle pain, nausea), anaphylaxis (severe allergic reaction), cardiac arrest, death, diarrhea, fever, hypotension (low blood pressure), hypoxemia (low oxygen levels in the blood), infection, myocardial infarction, perforation, pneumonia, pulmonary embolism (blood clot in the lung), respiratory distress, and thrombophlebitis (blood clot). Other risks reported after anti-reflux surgery procedures include bloating, nausea, dysphagia (difficulty swallowing), odynophagia (painful swallowing), retching, and vomiting.

Potential risks associated specifically with the LINX Reflux Management System include achalasia (lower part of esophagus does not relax), bleeding, cough, death, decreased appetite, device erosion, device explant/re-operation, device failure, device migration (device does not appear to be at implant site), diarrhea, dyspepsia (indigestion), dysphagia (difficulty swallowing), early satiety (feeling full after eating a small amount of food), esophageal spasms, esophageal stricture, flatulence, food impaction, globus sensation (sensation of a lump in the throat), hiccups, inability to belch or vomit, increased belching, infection, impaired gastric motility, injury to the esophagus, spleen, or stomach, nausea, odynophagia (painful swallowing), organ damage caused by device migration, pain, peritonitis (inflammation of the peritoneum), pneumothorax (collapsed lung), regurgitation, saliva/mucus build-up, swallow-Induced syncope (fainting), stomach bloating, ulcer, vomiting, weight loss, and worsening of preoperative symptoms (including but not limited to dysphagia or heartburn).

101161-221006 © Ethicon, US LLC 2022


Manufactured by:
Torax® Medical, Inc.
4188 Lexington Avenue North
Shoreview, Minnesota 55126, USA

©Ethicon, Inc. 2022. All rights reserved. 100324-220804

2022 Ethicon Product Catalog


© Ethicon US, LLC. 2022.
For complete indications, contraindications, warnings, precautions, and adverse reactions, please reference full package insert.
This site is published by Ethicon US, LLC, which is solely responsible for its contents, and is intended for U.S. audiences only.
This site is intended for Healthcare Professionals. If you are a patient, it is important that you discuss information about the benefits and risks of products with your doctor.
Last updated February 20, 2019. The third-party trademarks used herein are trademarks of their respective owners. Data and usage fees may apply. See your carrier for more information.

Ethicon
         
  LinkedIn

 

Twitter

 

YouTube

 

 
Johnson and Johnson logo
Johnson & Johnson
  • Privacy Policy
  • Legal Notice
  • Do Not Sell or Share My Personal Information
  • Contact Us
  • J&J Institute
  • Accessibility Statement
  • Cookie Policy
English (United States)

© Medical Device Business Services, Inc. 2021-2023. All rights reserved.

This information is intended for use by customers, patients, and healthcare professionals in the United States only. We recognize that the Internet is a global communications medium; however, laws, regulatory requirements, and product information for medical products can vary from country to country. The product information included here may not be appropriate for use outside the United States, and the information from other sites you visit may not be appropriate for use in the United States.

You are about to leave jnjmedtech.com. By clicking to continue, you will be taken to a web site governed by their own Legal and Privacy Policies.

Yes, Continue to External Site No, Stay Here